Greg Kricorian

2.0k total citations · 2 hit papers
34 papers, 1.4k citations indexed

About

Greg Kricorian is a scholar working on Dermatology, Immunology and Hematology. According to data from OpenAlex, Greg Kricorian has authored 34 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Dermatology, 16 papers in Immunology and 10 papers in Hematology. Recurrent topics in Greg Kricorian's work include Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (13 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Greg Kricorian is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (14 papers), Dermatology and Skin Diseases (13 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Greg Kricorian collaborates with scholars based in United States, Canada and United Kingdom. Greg Kricorian's co-authors include Paul Klekotka, Kim Papp, Richard G. Langley, Ajay Nirula, Leon Kircik, Kenneth G. Gross, Alice B. Gottlieb, Elizabeth H. Thompson, Kristian Reich and C. Paul and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Greg Kricorian

33 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

2016 376 citations Kim Papp, Kristian Reich et al. British Journal of Dermatology profile →
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target

2024 39 citations Michael Croft, Ehsanollah Esfandiari et al. American Journal of Clinical Dermatology profile →

Peers

Countries citing papers authored by Greg Kricorian

Since Specialization

Citations

This map shows the geographic impact of Greg Kricorian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Kricorian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Kricorian more than expected).

Fields of papers citing papers by Greg Kricorian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Kricorian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Kricorian. The network helps show where Greg Kricorian may publish in the future.

Co-authorship network of co-authors of Greg Kricorian

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Kricorian. A scholar is included among the top collaborators of Greg Kricorian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Kricorian. Greg Kricorian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis 2025 ·Immunotherapy ·Emma Guttman‐Yassky, Eric L. Simpson, Robert Bissonnette, Lawrence F. Eichenfield, Kenji Kabashima, Paula Carolina Luna, Jana Hercogová, Lynda Spelman, Margitta Worm, Ehsanollah Esfandiari, Takahiro Arai, (unknown), Prista Charuworn, Andrea Wang, Greg Kricorian	5
2	OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target breakdown → 2024 ·American Journal of Clinical Dermatology ·Michael Croft, Ehsanollah Esfandiari, (unknown), Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard B. Warren, Andreas Wollenberg, Emma Guttman‐Yassky	39
3	Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis 2023 ·The Journal of Rheumatology ·Jeffrey R. Curtis, Paul Emery, Greg Kricorian, Priscilla K. Yen, David H. Collier, Vivian P. Bykerk, Boulos Haraoui	0
4	Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry 2020 ·ACR Open Rheumatology ·Dimitrios A. Pappas, Ying Shan, (unknown), Greg Kricorian, (unknown), Sabrina Rebello, (unknown), Neil A. Accortt, Scott Stryker	4
5	Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data 2020 ·Rheumatology International ·Dimitrios A. Pappas, Heather J. Litman, (unknown), Greg Kricorian, (unknown), Sabrina Rebello, (unknown), Neil A. Accortt, Scott Stryker	5
6	Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial 2019 ·Rheumatology and Therapy ·Stanley Cohen, (unknown), (unknown), Bradley S. Stolshek, (unknown), Hao Zhang, Girish Aras, Greg Kricorian, James Chung	13
7	Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases 2016 ·Lara D. Veeken ·Ajay Nirula, Jon Nilsen, Paul Klekotka, Greg Kricorian, Ngozi Erondu, Jennifer E. Towne, Chris B. Russell, Roland Martinꝉ, Alison Budelsky	42
8	Clinical meaningfulness of complete skin clearance in psoriasis 2016 ·Journal of the American Academy of Dermatology ·Bruce Strober, Kim Papp, Mark Lebwohl, Kristian Reich, C. Paul, Andrew Blauvelt, Kenneth B. Gordon, Cassandra E. Milmont, Hema N. Viswanathan, Joanne Li, Lionel Pinto, David J. Harrison, Greg Kricorian, Ajay Nirula, Paul Klekotka	93
9	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis 2014 ·Journal of the American Academy of Dermatology ·Kim Papp, Alan Menter, Bruce Strober, Greg Kricorian, Elizabeth H. Thompson, Cassandra E. Milmont, Ajay Nirula, Paul Klekotka	36
10	Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment 2014 ·Journal of the American Academy of Dermatology ·Kim Papp, Craig L. Leonardi, Alan Menter, Elizabeth H. Thompson, Cassandra E. Milmont, Greg Kricorian, Ajay Nirula, Paul Klekotka	93
11	A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis 2013 ·Journal of the American Academy of Dermatology ·Mark Lebwohl, Leon Kircik, Kristina Callis Duffin, David M. Pariser, Michele Hooper, Deborah Wenkert, Elizabeth H. Thompson, Jun Yang, Greg Kricorian, John Koo	21
12	A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis 2012 ·British Journal of Dermatology ·Alice B. Gottlieb, Richard G. Langley, Bruce Strober, Kim Papp, Paul Klekotka, (unknown), Elizabeth H. Thompson, M. Hooper, Greg Kricorian	99
13	Long-term etanercept in pediatric patients with plaque psoriasis 2010 ·Journal of the American Academy of Dermatology ·Amy S. Paller, Elaine C. Siegfried, Lawrence F. Eichenfield, David M. Pariser, Richard G. Langley, Kara Creamer, Greg Kricorian	72
14	5% 5‐Fluorouracil Cream for Treatment of Verruca Vulgaris in Children 2009 ·Pediatric Dermatology ·Julie Akiko Gladsjo, (unknown), James N. Bergman, Greg Kricorian, Bari B. Cunningham	27
15	Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks 2009 ·Journal of the American Academy of Dermatology ·(unknown), Shilpa Gattu, Judith Hong, (unknown), (unknown), Farah Malick, Greg Kricorian, John Koo	18
16	Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms 2007 ·Clinical Neuropharmacology ·William G. Ondo, Kapil D. Sethi, Greg Kricorian	30
17	5% 5-Fluorouracil Cream for the Treatment of Small Superficial Basal Cell Carcinoma: Efficacy, Tolerability, Cosmetic Outcome, and Patient Satisfaction 2007 ·Dermatologic Surgery ·Kenneth G. Gross, Leon Kircik, Greg Kricorian	104
18	Topical kinetin 0.1% lotion for improving the signs and symptoms of rosacea 2007 ·Clinical and Experimental Dermatology ·Jashin J. Wu, Gerald D. Weinstein, Greg Kricorian, (unknown), Jerry L. McCullough	30
19	Full face laser resurfacing: Therapy and prophylaxis for actinic keratoses and non‐melanoma skin cancer 2004 ·Lasers in Surgery and Medicine ·Shilesh Iyer, (unknown), Leyda E. Bowes, Greg Kricorian, Richard Fitzpatrick	55
20	Treatment of Basal Cell Carcinoma with the Pulsed Carbon Dioxide Laser: A Retrospective Analysis 2004 ·Dermatologic Surgery ·Shilesh Iyer, Leyda E. Bowes, Greg Kricorian, (unknown), Richard Fitzpatrick	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact